GLAXOSMITHKLINE PLC - SPONSORED ADR (GSK)

Historical Holders from Q1 2014 to Q3 2025

Symbol
GSK on NYSE
Type / Class
Equity / SPONSORED ADR
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
2.1K
Holdings value
$90.7K
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
5
Number of sells
-1
Average Value change %
0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of GLAXOSMITHKLINE PLC - SPONSORED ADR (GSK)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 2.1K $90.7K -$13.8K $43.16 5
2025 Q2 2.42K $93K -$31.9M $38.40 5
2025 Q1 825K $31.9M -$2.42M $38.74 6
2024 Q4 887K $30M -$6.27M $33.82 6
2024 Q3 1.09M $44.4M -$7.4M $40.88 7
2024 Q2 1.27M $48.9M -$473K $38.50 7
2024 Q1 1.28M $54.9M +$448K $42.87 9
2023 Q4 1.27M $47.1M -$923K $37.06 8
2023 Q3 1.3M $47M +$724K $36.25 9
2023 Q2 1.29M $45.5M -$504K $35.64 9
2023 Q1 1.29M $45.9M +$865K $35.58 9
2022 Q4 1.31M $46.4M -$40.6M $35.14 13
2022 Q3 2.67M $78.7M -$13.6B $29.43 31
2022 Q2 320M $13.9B -$355M $43.53 823
2022 Q1 331M $14.4B +$157M $43.56 913
2021 Q4 327M $14.4B +$217M $44.10 904
2021 Q3 324M $12.4B +$151M $38.21 775
2021 Q2 320M $12.7B -$342M $39.82 787
2021 Q1 317M $11.3B +$543M $35.69 764
2020 Q4 302M $11.1B +$193M $36.80 808
2020 Q3 298M $11.2B -$400M $37.64 819
2020 Q2 305M $12.5B -$291M $40.79 829
2020 Q1 312M $11.8B +$918M $37.89 809
2019 Q4 288M $13.5B +$322M $46.99 884
2019 Q3 282M $12B +$122M $42.68 800
2019 Q2 279M $11.2B -$33.5M $40.02 795
2019 Q1 281M $11.7B +$201M $41.79 837
2018 Q4 274M $10.5B +$76M $38.21 791
2018 Q3 273M $11B +$215M $40.17 783
2018 Q2 268M $10.8B -$297M $40.31 781
2018 Q1 276M $10.8B +$122M $39.07 771
2017 Q4 273M $9.68B +$1.02B $35.47 753
2017 Q3 243M $9.85B +$527M $40.60 736
2017 Q2 230M $9.9B +$361M $43.12 772
2017 Q1 221M $9.34B +$526M $42.16 779
2016 Q4 209M $8.03B +$51.5M $38.51 756
2016 Q3 207M $8.93B -$126M $43.13 727
2016 Q2 210M $9.11B +$232M $43.34 730
2016 Q1 205M $8.34B -$335M $40.55 711
2015 Q4 215M $8.69B -$122M $40.35 708
2015 Q3 218M $8.39B -$437M $38.45 692
2015 Q2 232M $9.68B -$829M $41.65 708
2015 Q1 250M $11.5B -$115M $46.15 726
2014 Q4 254M $10.8B -$554M $42.74 717
2014 Q3 265M $12.2B -$645M $45.97 693
2014 Q2 278M $14.9B +$862M $53.48 712
2014 Q1 262M $14B -$181M $53.43 704